DK3204386T3 - Substituerede aminopurinforbindelser, sammensætninger deraf og fremgangsmåder til behandling dermed - Google Patents

Substituerede aminopurinforbindelser, sammensætninger deraf og fremgangsmåder til behandling dermed Download PDF

Info

Publication number: DK3204386T3
Authority: DK; Denmark
Prior art keywords: aminopury; substituted; compositions; compounds; treatment
Prior art date: 2014-10-06

Application number

DK15848476.6T

Other languages

English (en)

Inventor

Matthew Alexander

Joshua Hansen

Dehua Huang

Brandon Jeffy

Jim Leisten

Mehran Moghaddam

Heather Raymon

Kimberly Schwarz

Marianne Sloss

Eduardo Torres

Shuichan Xu

Jingjing Zhao

John Fredrerick Boylan

Robert Hubbard

Raj K Raheja

Tam Minh Tran

Sogole Bahmanyar

Original Assignee

Signal Pharm Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-10-06

Filing date

2015-10-05

Publication date

2021-05-25

2015-10-05 Application filed by Signal Pharm Llc filed Critical Signal Pharm Llc

2021-05-25 Application granted granted Critical

2021-05-25 Publication of DK3204386T3 publication Critical patent/DK3204386T3/da

Links

150000001875 compounds Chemical class 0.000 title 1
239000000203 mixture Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/50—Three nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

DK15848476.6T 2014-10-06 2015-10-05 Substituerede aminopurinforbindelser, sammensætninger deraf og fremgangsmåder til behandling dermed DK3204386T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201462060339P	2014-10-06	2014-10-06
PCT/US2015/053941 WO2016057370A1 (en)	2014-10-06	2015-10-05	Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith

Publications (1)

Publication Number	Publication Date
DK3204386T3 true DK3204386T3 (da)	2021-05-25

Family

ID=55632334

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK15848476.6T DK3204386T3 (da)	2014-10-06	2015-10-05	Substituerede aminopurinforbindelser, sammensætninger deraf og fremgangsmåder til behandling dermed

Country Status (28)

Country	Link
US (8)	US9512124B2 (da)
EP (2)	EP3204386B1 (da)
JP (4)	JP6884701B2 (da)
KR (2)	KR20230035424A (da)
CN (2)	CN113248506A (da)
AR (2)	AR102171A1 (da)
AU (2)	AU2015328414B2 (da)
CA (1)	CA2963639C (da)
CL (1)	CL2017000820A1 (da)
CO (1)	CO2017003838A2 (da)
CY (1)	CY1124173T1 (da)
DK (1)	DK3204386T3 (da)
EA (1)	EA201790779A1 (da)
EC (1)	ECSP17026210A (da)
ES (2)	ES2871142T3 (da)
HR (1)	HRP20210656T1 (da)
HU (1)	HUE054694T2 (da)
IL (2)	IL251566B (da)
LT (1)	LT3204386T (da)
MX (2)	MX388321B (da)
PL (1)	PL3204386T3 (da)
PT (1)	PT3204386T (da)
RS (1)	RS61884B1 (da)
SG (2)	SG11201702759XA (da)
SI (1)	SI3204386T1 (da)
SM (1)	SMT202100302T1 (da)
TW (1)	TW201629063A (da)
WO (1)	WO2016057370A1 (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20230035424A (ko) *	2014-10-06	2023-03-13	시그날 파마소티칼 엘엘씨	치환된 아미노퓨린 화합물, 그의 조성물 및 그를 사용한 치료 방법
EP3233808B1 (en)	2014-12-16	2021-07-14	Signal Pharmaceuticals, LLC	Medical uses comprising methods for measurement of inhibition of c-jun n-terminal kinase in skin
CA2975260C (en)	2015-01-29	2024-05-21	Signal Pharmaceuticals Llc	Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
ES2803650T3 (es)	2015-03-18	2021-01-28	Bristol Myers Squibb Co	Compuestos heterocíclicos útiles como inhibidores de TNF
ES2797805T3 (es)	2015-03-18	2020-12-03	Bristol Myers Squibb Co	Compuestos heterocíclicos tricíclicos sustituidos
BR112017019731A2 (pt)	2015-03-18	2018-05-22	Bristol-Myers Squibb Company	compostos heterocíclicos tricíclicos úteis como inibidores de tnf
ES2994877T3 (en)	2015-07-24	2025-02-03	Celgene Corp	Methods of synthesis of (1r,2r,5r)-5-amino-2-methylcyclohexanol hydrochloride and intermediates useful therein
EP3331889B1 (en)	2015-08-03	2020-09-23	Bristol-Myers Squibb Company	Cyclic compounds useful as modulators of tnf alpha
BR112018070163A2 (pt) *	2016-04-01	2019-01-29	Signal Pharm Llc	compostos de aminopurina substituída, composições e métodos de tratamento
HRP20211546T1 (hr) *	2016-04-01	2022-01-07	Signal Pharmaceuticals, Llc	(1s,4s)-4-(2-(((3s,4r)-3-fluortetrahidro-2h-piran-4-il)amino)-8-((2,4,6-triklorfenil)amino)-9h-purin-9-il)-1 -metilcikloheksan-1 -karboksamid i postupci njegove uporabe
CN109563095B (zh) *	2016-06-02	2021-10-29	细胞基因公司	动物和人抗疟剂
TW201802093A (zh) *	2016-06-02	2018-01-16	西建公司	動物及人類抗錐蟲及抗利什曼原蟲藥劑
BR112020006599B1 (pt)	2017-10-04	2024-02-20	Celgene Corporation	Cápsulas compreendendo cis-4-[2-{[(3s,4r)-3-fluoro-oxan-4-il]amino}-8-(2,4,6-tricl oroanilino)-9h-purin-9-il]-1-metilciclohexano-1-carb oxamida
US10590136B2 (en) *	2017-10-04	2020-03-17	Celgene Corporation	Processes for the preparation of cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9H-purin-9-yl]-1-methylcyclohexane-1-carboxamide
TW202202498A (zh) *	2020-07-01	2022-01-16	大陸商四川海思科製藥有限公司	一種並環雜環衍生物及其在醫藥上的應用
US12084453B2 (en)	2021-12-10	2024-09-10	Incyte Corporation	Bicyclic amines as CDK12 inhibitors
CN114478326B (zh) *	2022-01-21	2023-10-03	安徽宁亿泰科技有限公司	一种苯嘧磺草胺关键中间体的合成方法
CN117964497B (zh) *	2024-01-26	2026-03-31	江西凯信生物医药有限公司	一种3,3-二氟环戊胺盐酸盐的合成方法
CN121758295A (zh) *	2024-09-30	2026-03-31	青岛清原化合物有限公司	一种亚氨基芳基类化合物及中间体的制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL99699A (en)	1990-10-10	2002-04-21	Autoimmune Inc	Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
FI109088B (fi)	1997-09-19	2002-05-31	Leiras Oy	Tabletti ja menetelmä sen valmistamiseksi
CZ27399A3 (cs) *	1999-01-26	2000-08-16	Ústav Experimentální Botaniky Av Čr	Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
US7672705B2 (en) *	2004-07-19	2010-03-02	Resonant Medical, Inc.	Weighted surface-to-surface mapping
US7759342B2 (en)	2005-01-13	2010-07-20	Signal Pharmaceuticals, Llc	Methods of treatment and prevention using haloaryl substituted aminopurines
US7723340B2 (en)	2005-01-13	2010-05-25	Signal Pharmaceuticals, Llc	Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
US7521446B2 (en) *	2005-01-13	2009-04-21	Signal Pharmaceuticals, Llc	Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
JP2009516707A (ja)	2005-11-18	2009-04-23	アストラゼネカ・アクチエボラーグ	固形製剤
JO3235B1 (ar)	2006-05-26	2018-03-08	Astex Therapeutics Ltd	مركبات بيررولوبيريميدين و استعمالاتها
CN101568544B (zh)	2006-10-27	2016-10-26	西格诺药品有限公司	包含4‑[9‑(四氢‑呋喃‑3‑基)‑8‑(2,4,6‑三氟‑苯氨基)‑9h‑嘌呤‑2‑基氨基]‑环己烷‑1‑醇的固体形式，其组合物，及其用途
PT2279731E (pt)	2008-04-23	2013-08-30	Farmasierra Mfg S L	Composição farmacêutica melhorada contendo ibuprofeno e codeína
US20130034495A1 (en)	2009-12-09	2013-02-07	Marie Georges Beauchamps	Isotopologues of 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol
US8680076B2 (en) *	2010-10-25	2014-03-25	Signal Pharmaceuticals, Llc	Methods of treatment, improvement and prevention using haloaryl substituted aminopurines
US8603527B2 (en)	2010-10-25	2013-12-10	Signal Pharmaceuticals, Llc	Pharmaceutical formulations of a substituted diaminopurine
US20160082015A1 (en)	2013-04-18	2016-03-24	President And Fellows Of Harvard College	Methods, compositions and kits for promoting motor neuron survival and treating and diagnosing neurodegenerative disorders
GB201321737D0 (en)	2013-12-09	2014-01-22	Ucb Pharma Sa	Therapeutic Agents
KR20230035424A (ko)	2014-10-06	2023-03-13	시그날 파마소티칼 엘엘씨	치환된 아미노퓨린 화합물, 그의 조성물 및 그를 사용한 치료 방법
HRP20211546T1 (hr)	2016-04-01	2022-01-07	Signal Pharmaceuticals, Llc	(1s,4s)-4-(2-(((3s,4r)-3-fluortetrahidro-2h-piran-4-il)amino)-8-((2,4,6-triklorfenil)amino)-9h-purin-9-il)-1 -metilcikloheksan-1 -karboksamid i postupci njegove uporabe

2015
- 2015-10-05 KR KR1020237006598A patent/KR20230035424A/ko not_active Withdrawn
- 2015-10-05 SG SG11201702759XA patent/SG11201702759XA/en unknown
- 2015-10-05 PT PT158484766T patent/PT3204386T/pt unknown
- 2015-10-05 JP JP2017538172A patent/JP6884701B2/ja active Active
- 2015-10-05 EP EP15848476.6A patent/EP3204386B1/en active Active
- 2015-10-05 WO PCT/US2015/053941 patent/WO2016057370A1/en not_active Ceased
- 2015-10-05 SG SG10202009598VA patent/SG10202009598VA/en unknown
- 2015-10-05 ES ES15848476T patent/ES2871142T3/es active Active
- 2015-10-05 LT LTEP15848476.6T patent/LT3204386T/lt unknown
- 2015-10-05 KR KR1020177010551A patent/KR102504849B1/ko active Active
- 2015-10-05 AU AU2015328414A patent/AU2015328414B2/en active Active
- 2015-10-05 CA CA2963639A patent/CA2963639C/en active Active
- 2015-10-05 ES ES20214685T patent/ES2980464T3/es active Active
- 2015-10-05 SI SI201531584T patent/SI3204386T1/sl unknown
- 2015-10-05 TW TW104132732A patent/TW201629063A/zh unknown
- 2015-10-05 SM SM20210302T patent/SMT202100302T1/it unknown
- 2015-10-05 EP EP20214685.8A patent/EP3822274B1/en active Active
- 2015-10-05 PL PL15848476T patent/PL3204386T3/pl unknown
- 2015-10-05 CN CN202110381676.XA patent/CN113248506A/zh active Pending
- 2015-10-05 HR HRP20210656TT patent/HRP20210656T1/hr unknown
- 2015-10-05 DK DK15848476.6T patent/DK3204386T3/da active
- 2015-10-05 CN CN201580065272.2A patent/CN107001372B/zh active Active
- 2015-10-05 MX MX2017004600A patent/MX388321B/es unknown
- 2015-10-05 HU HUE15848476A patent/HUE054694T2/hu unknown
- 2015-10-05 AR ARP150103202A patent/AR102171A1/es not_active Application Discontinuation
- 2015-10-05 EA EA201790779A patent/EA201790779A1/ru unknown
- 2015-10-05 US US14/874,513 patent/US9512124B2/en active Active
- 2015-10-05 RS RS20210632A patent/RS61884B1/sr unknown
2016
- 2016-10-27 US US15/335,619 patent/US9737541B2/en active Active
2017
- 2017-04-04 IL IL251566A patent/IL251566B/en active IP Right Grant
- 2017-04-04 CL CL2017000820A patent/CL2017000820A1/es unknown
- 2017-04-06 MX MX2021014531A patent/MX2021014531A/es unknown
- 2017-04-20 CO CONC2017/0003838A patent/CO2017003838A2/es unknown
- 2017-04-27 EC ECIEPI201726210A patent/ECSP17026210A/es unknown
- 2017-07-05 US US15/641,383 patent/US10149849B2/en active Active
2018
- 2018-10-24 US US16/169,414 patent/US10398700B2/en active Active
2019
- 2019-07-17 US US16/514,749 patent/US10646493B2/en active Active
- 2019-10-02 JP JP2019182133A patent/JP6987823B2/ja active Active
2020
- 2020-02-28 AU AU2020201486A patent/AU2020201486B2/en active Active
- 2020-04-13 US US16/846,503 patent/US10940152B2/en active Active
- 2020-09-01 IL IL277069A patent/IL277069B/en unknown
2021
- 2021-01-12 US US17/147,127 patent/US11590139B2/en active Active
- 2021-05-24 CY CY20211100444T patent/CY1124173T1/el unknown
- 2021-12-01 JP JP2021195105A patent/JP7196270B2/ja active Active
2022
- 2022-12-14 JP JP2022199122A patent/JP2023027269A/ja active Pending
2023
- 2023-01-11 US US18/095,670 patent/US20230158035A1/en not_active Abandoned
- 2023-03-09 AR ARP230100589A patent/AR128748A2/es unknown

Also Published As

Publication number	Publication date
ES2871142T3 (es)	2021-10-28
AR102171A1 (es)	2017-02-08
IL277069B (en)	2022-05-01
EA201790779A1 (ru)	2017-09-29
US11590139B2 (en)	2023-02-28
US9512124B2 (en)	2016-12-06
MX2017004600A (es)	2017-06-30
US10149849B2 (en)	2018-12-11
SG10202009598VA (en)	2020-10-29
AU2020201486B2 (en)	2021-07-08
AU2015328414A1 (en)	2017-04-27
US20160096841A1 (en)	2016-04-07
CL2017000820A1 (es)	2017-12-15
JP6987823B2 (ja)	2022-01-05
RS61884B1 (sr)	2021-06-30
HUE054694T2 (hu)	2021-09-28
MX2021014531A (es)	2022-01-06
ECSP17026210A (es)	2017-05-31
JP7196270B2 (ja)	2022-12-26
US20170042902A1 (en)	2017-02-16
CY1124173T1 (el)	2022-05-27
CO2017003838A2 (es)	2017-07-11
CA2963639C (en)	2023-07-04
EP3204386B1 (en)	2021-03-03
KR20170063740A (ko)	2017-06-08
US20170296546A1 (en)	2017-10-19
US20210128565A1 (en)	2021-05-06
US10646493B2 (en)	2020-05-12
US9737541B2 (en)	2017-08-22
LT3204386T (lt)	2021-07-12
PL3204386T3 (pl)	2021-09-20
CN113248506A (zh)	2021-08-13
AU2020201486A1 (en)	2020-03-19
EP3204386A4 (en)	2018-04-18
SI3204386T1 (sl)	2021-08-31
US20200237768A1 (en)	2020-07-30
MX388321B (es)	2025-03-19
AU2015328414B2 (en)	2020-03-19
HRP20210656T1 (hr)	2021-07-23
EP3822274A1 (en)	2021-05-19
JP2023027269A (ja)	2023-03-01
CN107001372B (zh)	2021-04-27
JP2017530199A (ja)	2017-10-12
US10940152B2 (en)	2021-03-09
NZ730753A (en)	2024-02-23
PT3204386T (pt)	2021-05-31
CA2963639A1 (en)	2016-04-14
ES2980464T3 (es)	2024-10-01
SG11201702759XA (en)	2017-05-30
SMT202100302T1 (it)	2021-07-12
JP2020033352A (ja)	2020-03-05
US20190091230A1 (en)	2019-03-28
TW201629063A (zh)	2016-08-16
US10398700B2 (en)	2019-09-03
IL251566A0 (en)	2017-05-29
EP3822274B1 (en)	2024-03-06
AR128748A2 (es)	2024-06-12
KR20230035424A (ko)	2023-03-13
IL251566B (en)	2020-09-30
US20190336507A1 (en)	2019-11-07
KR102504849B1 (ko)	2023-03-02
WO2016057370A1 (en)	2016-04-14
BR112017006998A2 (pt)	2018-01-16
US20230158035A1 (en)	2023-05-25
JP2022033858A (ja)	2022-03-02
NZ767954A (en)	2024-02-23
CN107001372A (zh)	2017-08-01
JP6884701B2 (ja)	2021-06-09
EP3204386A1 (en)	2017-08-16
IL277069A (en)	2020-10-29

Publication	Publication Date	Title
DK3092256T3 (da)	2022-06-20	Forbindelser og sammensætninger til immunterapi
DK3676297T3 (da)	2023-08-14	Forbindelser, sammensætninger og fremgangsmåder
DK3102673T3 (da)	2020-07-06	Fremgangsmåder og sammensætninger til behandling af beta-talassæmi
DK3161124T3 (da)	2020-06-29	Endofytter, associerede sammensætninger og fremgangsmåder til anvendelse deraf
DK3125927T3 (da)	2021-04-19	Fremgangsmåder og sammensætninger til immunmodulering
DK3888658T3 (da)	2024-03-18	Eif4-a-inhiberende forbindelser og fremgangsmåder relateret dertil
DK3215147T3 (da)	2024-04-02	Neurodæmpende norketamin-forbindelser og fremgangsmåder
DK3108009T3 (da)	2021-06-07	Fremgangsmåder og sammensætninger til DNA-profilering
DK3291832T3 (da)	2025-12-08	Nanopartikelkompositioner til langvarig behandling
DK3495023T3 (da)	2020-07-20	Semifluorerede forbindelser og sammensætninger deraf
DK3227262T3 (da)	2020-08-10	Sulfidalkyl og pyridyl-revers-sulfonamidforbindelser til hbv-behandling
DK3119808T3 (da)	2019-10-28	Antistofsammensætninger til tumorbehandling
DK3072835T3 (da)	2019-07-29	Fremgangsmåde til fremføring
HUE053485T2 (hu)	2021-06-28	Készítmények és eljárások meibom-mirigy diszfunkció kezelésére
HUE049175T2 (hu)	2020-09-28	Eljárás anti-CD79b immunkonjugátumok alkalmazására
DK3134130T3 (da)	2019-08-26	Sammensætninger og fremgangsmåder til behandling af hæmoglobinopatier
DK3137605T3 (da)	2020-12-14	Sammensætninger og fremgangsmåder til modulering af angiopoietin-lignende-3-ekspression
LT3240895T (lt)	2022-04-11	Kompozicijos ir būdai, skirti baltymų glikozilinimui
DK3200815T3 (da)	2021-05-10	Fremgangsmåder og sammensætninger til behandling af cancer
DK3102200T3 (da)	2023-05-22	Terapeutisk forbindelse og sammensætning
DK3265087T3 (da)	2020-10-19	Fremgangsmåde til behandling med tradipitant
DK3353168T3 (da)	2023-10-02	Forbindelser og fremgangsmåder til at inhibere jak
DK3125898T3 (da)	2020-03-30	Farmakofor til trail-induktion
DK3209696T3 (da)	2021-08-09	Fremgangsmåder og sammensætninger til diagnosticering og behandling af glioblastom
DK3110446T3 (da)	2022-02-28	Fremgangsmåder og sammensætninger til behandling af Siglec-8-associerede sygdomme